Abstract
The approval of monoclonal antibodies for therapy of hematologic malignacies (Rituxan®, Mylotarg™, Campath ®) renewed the interest in antibodies as potential new treatment options for cancer patients. Antibodies are effective in inhibiting tumor cell growth , inducing apoptosis, and activating host effector mechanisms for tumor cell killing. Monoclonal antibodies can be clinically effective as monotherapy, as targeting agents delivering either potent cytotoxic drugs or radionuclides as well as in combination with conventional chemotherapies. Advances in antibody engineering provided new capabilities to reduce immunogenicity, alter half life, increase effector functions, and increase tumor targeting for optimal therapeutic modalities requiring chronic dosing regimens. During the next decade, as new tumor-specific surface antigens are discovered and the linkage between genes and function is better understood, new targets will be identified for regulating tumor cell growth by engineered antibodies with agonist or antagonist activity. Additionally, antibody engineering will allow for more efficient radionuclide or cytotoxic drug targeting or lead to more selective activation of relevant host effector mechanisms, leading to a safe and effective therapy of cancer.
Current Pharmaceutical Biotechnology
Title: Future Approaches for Treating Hematologic Disease
Volume: 2 Issue: 4
Author(s): M. Reff, G. Braslawsky and N. Hanna
Affiliation:
Abstract: The approval of monoclonal antibodies for therapy of hematologic malignacies (Rituxan®, Mylotarg™, Campath ®) renewed the interest in antibodies as potential new treatment options for cancer patients. Antibodies are effective in inhibiting tumor cell growth , inducing apoptosis, and activating host effector mechanisms for tumor cell killing. Monoclonal antibodies can be clinically effective as monotherapy, as targeting agents delivering either potent cytotoxic drugs or radionuclides as well as in combination with conventional chemotherapies. Advances in antibody engineering provided new capabilities to reduce immunogenicity, alter half life, increase effector functions, and increase tumor targeting for optimal therapeutic modalities requiring chronic dosing regimens. During the next decade, as new tumor-specific surface antigens are discovered and the linkage between genes and function is better understood, new targets will be identified for regulating tumor cell growth by engineered antibodies with agonist or antagonist activity. Additionally, antibody engineering will allow for more efficient radionuclide or cytotoxic drug targeting or lead to more selective activation of relevant host effector mechanisms, leading to a safe and effective therapy of cancer.
Export Options
About this article
Cite this article as:
M. Reff , G. Braslawsky and N. Hanna , Future Approaches for Treating Hematologic Disease, Current Pharmaceutical Biotechnology 2001; 2 (4) . https://dx.doi.org/10.2174/1389201013378626
DOI https://dx.doi.org/10.2174/1389201013378626 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting of Leukemia-Initiating Cells to Develop Curative Drug Therapies: Straightforward but Nontrivial Concept
Current Cancer Drug Targets An Epigenetic Approach to Pancreatic Cancer Treatment: The Prospective Role of Histone Deacetylase Inhibitors
Current Cancer Drug Targets Targeting the p53-Family in Cancer and Chemosensitivity: Triple Threat
Current Drug Targets Comparative Genomic Hybridization: A Valuable Tool for Genome-Scale Analysis of Rodent Cancer Models
Current Genomics Exploitation of Apoptosis Pathways for Childhood Leukemia
Current Pediatric Reviews Cancer Immunotherapy Using Gene-Modified Dendritic Cells
Current Gene Therapy Epigenetic Modulation: A Promising Avenue to Advance Hematopoietic Stem Cell-Based Therapy for Severe Autoimmune Disorders
Epigenetic Diagnosis & Therapy (Discontinued) Procarbazine – A Traditional Drug in the Treatment of Malignant Gliomas
Current Medicinal Chemistry Prevention of Immune-mediated Transfusion-related Acute Lung Injury; from Bloodbank to Patient
Current Pharmaceutical Design Recent Developments in Targeting Breast Cancer Stem Cells
Recent Patents on Regenerative Medicine Inflammation and Cancer: When NF-κB Amalgamates the Perilous Partnership
Current Cancer Drug Targets subject Index To Volume 2
Current Pharmaceutical Biotechnology Anticancer Drugs in Liposomal Nanodevices: A Target Delivery for a Targeted Therapy
Current Topics in Medicinal Chemistry Antisense Oligonucleotides in the Treatment of Cerebral Gliomas. Review of Concerning Patents
Recent Patents on CNS Drug Discovery (Discontinued) Combinations of Plant Polyphenols & Anti-Cancer Molecules: A Novel Treatment Strategy for Cancer Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia
Anti-Cancer Agents in Medicinal Chemistry Diaryl Urea: A Privileged Structure in Anticancer Agents
Current Medicinal Chemistry Advances in Stem Cell Therapy for Leukemia
Current Stem Cell Research & Therapy Novel and Emerging Drugs for Systemic Lupus Erythematosus: Mechanism of Action and Therapeutic Activity
Current Medicinal Chemistry Lenalidomide – Current Understanding of Mechanistic Properties
Anti-Cancer Agents in Medicinal Chemistry